Skip to main content
OpenTrials
Completed

NCT Number: NCT06971315

Impact of Vitamin C on Pain Detection and Tolerance Threshold

Non-opioid treatments are increasingly sought after for managing acute pain. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., Advil, Motrin, Naproxen) combined with acetaminophen (e.g., Tylenol) have become an alternative for relieving acute pain. However, many patients cannot tolerate or have contraindications to NSAIDs and acetaminophen.

There is therefore an urgent need for studies evaluating the analgesic effects of vitamin C in the context of acute pain. Our study is conducted with healthy volunteer participants receiving either vitamin C or a placebo to assess the analgesic effect of vitamin C by comparing pain detection and tolerance thresholds.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital du Sacre-Coeur de Montreal

Montreal, Quebec, H4J 1C5, Canada

About this study

Opioid-free treatments are increasingly sought for acute pain and NSAIDs have become an alternative to treat acute MSK pain and are often administered in addition to acetaminophen. However, NSAIDs can produce important adverse events and are contraindicated in many patients with comorbidities (e.g., heart disease, renal failure). Similarly, acetaminophen is contraindicated in patients with active liver disease or severe hepatic impairment.

Vitamin C has shown opioid sparing and anti-inflammatory effects mostly in postoperative contexts. Vitamin C has also demonstrated very low toxicity and rare contraindications at the dosage used in this study. Demonstrating that vitamin C increases pain detection and tolerance thresholds, thereby exhibiting an analgesic effect, could offer a valuable alternative or adjunct for patients who cannot tolerate or have contraindications to NSAIDs or acetaminophen, helping to reduce opioid use. With an aging population, the number of affected patients is expected to rise significantly.

The primary outcome is the pressure pain detection threshold (PPDT) measured with an algometer one to three hours after the last dose of the study drug (24 hours after the first dose of vitamin C or placebo).

Secondary outcomes are PPDT one to three hours after the first study drug dose, PPTT one to three hours after the initial dose and last dose of the study drug, and adverse events from the algometer or the vitamin C.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 to 65 years old;
  • No acute or chronic pain;
  • No pain medication;
  • French or English-speaking

Exclusion criteria

  • Currently using vitamin C supplements;
  • Pain in the last week or active cancer;
  • Unavailable for follow-up;
  • Allergy to milk (lactose in the placebo), or vitamin C,
  • Treated with cyclosporine or warfarin (interaction with vitamin C);
  • Pre-existing oxalate nephropathy, liver cirrhosis or hemochromatosis;
  • Evidence of joint or overlying skin infection in the areas of testing.

Treatment and study plan

Vitamin C

Dietary Supplement

Three doses of 900 mg vitamin C taken orally (baseline, 12 hours and 24 hours)

Placebo

Other

Three doses of 900 mg placebo taken orally (baseline, 12 hours and 24 hours)

Primary outcomes

  1. Pressure pain detection threshold (PPDT)

    Time frame: 24 hours

    Pressure pain detection threshold (PPDT) measured with an algometer one to three hours after the last dose of the study drug (24 hours after the first dose of vitamin C or placebo).

Secondary outcomes

  1. Pressure pain detection threshold one to three hours after the first study drug dose

    Time frame: 1 hours

    Pressure pain detection threshold (PPDT) measured with an algometer one to three hours after the first dose of the study drug

  2. Pressure pain tolerance threshold (PPTT) one to three hours after the last dose of the study drug

    Time frame: 24 hours

    Pressure pain tolerance threshold (PPTT) measured with an algometer one to three hours after the last dose of the study drug

  3. Pressure pain tolerance threshold (PPTT) one to three hours after the first dose of the study drug

    Time frame: 1 hour

    Pressure pain tolerance threshold (PPTT) measured with an algometer one to three hours after the first dose of the study drug

Sponsors and collaborators

Lead sponsor

Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Other

Registry information

Official study title

Impact of Vitamin C on Pain Detection and Tolerance Threshold: a Double-blind Randomized Controlled Trial

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 14, 2025
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.